Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (February 2025)
24 slides from Adalta's investor presentation, Feb 7, 2025
Slide 1: Commercialising Cellular Immunotherapies "East to West"
COMMERCIALISING CELLULAR IMMUNOTHERAPIES “EAST TO WEST” ADALTA LIMITED (ASX:1AD) | INVESTOR PRESENTATION | FEBRUARY 2025 AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 1
Slide 2: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invit
Slide 3: AdAlta: Next Generation Cell & Protein Therapeutics
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS In-license next generation clinical stage assets from Asia, establish Western manufacturing and generate clinical data for on-licensing AdAlta is a clinical Leverages our unique skills, regional ecosystem and business model to create a leader in ce
Slide 4: "East to West" Strategy Central to AdAlta's Growth
“EAST TO WEST” STRATEGY CENTRAL TO ADALTA’S GROWTH AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 44
Slide 5: "East to West" Strategy Overview
“EAST TO WEST” STRATEGY OVERVIEW Substantial value inflection potential by bringing “Eastern” cellular immunotherapy innovations to “Western” regulated markets AdAlta has clear aspirational growth targets for its Combining Asia's innovative T cell therapies for solid cancers and “East to West” strat
Slide 6: The Market Opportunity
THE MARKET OPPORTUNITY T cell solid cancer therapy: the next frontier for cellular immunotherapy In 2024, FDA approved two What is T-cell therapy? 6 FDA-approved CAR-T T cell therapies for solid therapies since 2017 cancer (melanoma, Involves re-engineering and transformed blood cancer sarcoma), ope
Slide 7: Accessing Quality Assets from Asia
ACCESSING QUALITY ASSETS FROM ASIA Quality Asia cellular Flow of innovation from Asia to the West is hampered by: lack of capital in Asia, lack of Western immunotherapy pipeline experience and networks, opportunity cost for large biopharma to conduct due diligence, difficulty aiming to reach West tr
Slide 8: Becoming a Valuation Multiplier for Asian Partners
BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS 3 In-license market leading 3 assets from Asia (“East”): 1 Low acquisition cost. By financing to next inflection On-licensing: point AdAlta acquires a Establish global share of the asset at exit manufacturing network and on-license to commercialisat
Slide 9: Value at Exit: Phase I CAR-T Cell Therapy Transactions
VALUE AT EXIT: PHASE I CAR-T CELL THERAPY TRANSACTIONS Total Upfront Date Drug(s) Licensor Licensee Deal stage Lead indications value (US$m) (US$m) DLL3 targeting autologous Phase 1 Nov-23 SCLC, LCNEC 1,110 100 CAR-T cell therapy (ongoing; US) In vivo CD19 CAR-T cell Phase 1b Aug-23 r/r B-cell ALL,
Slide 10: Leveraging AdAlta's Competitive Advantages
LEVERAGING ADALTA’S COMPETITIVE ADVANTAGES Strategic asset sourcing discipline Capital-light and risk managed • T cell therapies for solid cancers • AdAlta managed; JV/asset financed • Differentiated, multi-functional • Defined investment in clinically product design derisked asset • Clinical data i
Slide 11: Progress and Potential
PROGRESS AND POTENTIAL Australian clinical trial data facilitates We are here pivotal studies, today licensing agreements First IND and asset sales approval (F) Three high value First technology assets secured (F) Three in-licensing transfer to 2028+ term sheets commence (F) “East to West” cell sign
Slide 12: Three Assets Under Exclusive Due Diligence
THREE ASSETS UNDER EXCLUSIVE DUE DILIGENCE First in-licensing term sheet Second in-licensing term sheet Third in-licensing term sheet Lung, mesothelioma, ovarian, cervical, Endothelial solid cancers incl. colorectal, Target cancer markets Gastric, gynaecological and epithelial pancreatic, colorectal
Slide 13: 1. Armoured CAR-T (First Term Sheet)
1. ARMOURED CAR-T (FIRST TERM SHEET) Target market Advanced, solid cancer patient: • Multiple solid cancers including lung, mesothelioma, ovarian, cervical, pancreatic, colorectal sustained response to armored-CAR-T • More than 1.5 million relapsed, refractory or metastatic patients requiring second
Slide 14: 2. First in Class CAR-T (Second Term Sheet)
2. FIRST IN CLASS CAR-T (SECOND TERM SHEET) Target market • Applicable for a wide range of endothelial solid cancers including colorectal, gastric, and lung Complete resolution of • More than 1.5 million relapsed or refractory patients worldwide each year malignant ascites in Stage IV GI cancer pati
Slide 15: 3. First in Class CAR-T (Third Term Sheet)
3. FIRST IN CLASS CAR-T (THIRD TERM SHEET) Target market • Gastric, gynaecological and other epithelial cancers Comparative efficacy versus • More than 1.5 million relapsed or refractory patients worldwide each year standard of care • 150,000 advanced gastric cancer patients each year 38-46 40 >40 P
Slide 16: AD-214: A New Approach to Fibrosis Available for Partnering
AD-214: A NEW APPROACH TO FIBROSIS AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 16 16
Slide 17: Monetising Fibrosis Disease Drug Candidate AD-214
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214 Investment to date has built strong value proposition Key Priority: Seek out-licensing or third-party investment to unlock next level of value First in class molecule targeting established mode ✓ Competitively positioned as only antibody-like Advisor
Slide 18: Underserved and Large Fibrotic Disease Market
UNDERSERVED AND LARGE FIBROTIC DISEASE MARKET IPF market is underserved today Many other fibrosis market opportunities • Poor efficacy: Existing therapies slow but do not halt progression and do not significantly extend life expectancy • Side effects: Their side effects result in 30-50% of patients
Slide 19: Pharma Companies Value IPF/Fibrosis Assets
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS Upfront payment to Contingent Clinical Phase at Date Licensor/target Licensee/acquirer Transaction licensor milestones transaction Aug-22 License US$100m US$600m 2 complete Apr-20 Acquisition US$45m Not disclosed 2a complete Nov-19 Acquisition US$390m US$1,
Slide 20: Corporate Information
CORPORATE INFORMATION AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 20 20
Slide 21: Corporate Snapshot
CORPORATE SNAPSHOT AdAlta Limited Code ASX:1AD Specialist in next-generation cell and protein therapeutics for fatal diseases Market Capitalisation $11.0m Enterprise Value $9.4m First three term sheets signed of "East-to- Cash $1.6m West" cell therapy strategy, with team and network in place Signifi
Slide 22: Experienced Team with Global Reach
EXPERIENCED TEAM WITH GLOBAL REACH Board Executive “East-to-West” Strategy AD-214: Fibrosis Paul MacLeman, DVM Angus Tester, PhD Kevin Lynch TBA - engaged Chair Senior Manager, Consultant CMO Consultant CMO Projects and Programs Tim Oldham, PhD Prof Andrew Wilks Joseph Tyler CEO / Managing Director
Slide 23: Transaction-Based Growth Strategy Is Being Delivered
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED “East to West” cellular The first three assets under Experienced team and accessible immunotherapy growth strategy exclusive due diligence for the “East global network ready to execute a leveraging regional and business to West” clinical pipeline
Slide 24: For More Information Please Contact
FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 T.OLDHAM@ADALTA.COM.AU INVESTOR RELATIONS THE CAPITAL NETWORK JULIA MAGUIRE +61 2 7257 7338 JULIA@THECAPITALNETWORK.COM.AU WWW.ADALTA.COM.AU AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 24